Sodium Thiosulfate Injection for Calcium Deposits in Connective Tissue Diseases
Tests sodium thiosulfate injected into calcium deposits in adults with scleroderma or related diseases.
Key facts
- Who runs it
- Robyn T. Domsic, MD, MPH
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Intralesional Injection of STS in Treatment of Calcinosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 17 Mar 2025
- Expected to end
- 1 May 2029
- Type of study
- Interventional
- Treatments tested
- Sodium Thiosulfate (STS)
- Record updated
- 5 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with systemic sclerosis, mixed connective tissue disease or inflammatory myopathy who have calcium deposits (calcinosis) and need symptom relief.
- Age
- Over 18 years
- Sex
- All sexes can join
- Disease stage
- A clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy. Calcinosis must show on an x-ray or ultrasound.
Main reasons for not taking part
- Pregnant women cannot join
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy
- Must be over 18 years of age
- Participants must be competent to give informed consent
- Participants must have radiographic evidence (xray or ultrasound) of calcinosis
- Participants must need symptomatic relief
Who cannot take part
- Pregnant women will be excluded
Where in United States
- UPMC Arthritis and Autoimmunity CenterPittsburgh, United StatesContact: Office ManagerTaking people
About the trial
What the trial wants to find out
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
The group in the trial
- Sodium thiosulfate (STS)Treatment being tested
Open label, single-arm, receiving 1-5ml of STS (250mg/ml) sodium thiosulfate (STS) injections to calcinosis lesions.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease
- Plain-language title
- Sodium Thiosulfate Injection for Calcium Deposits in Connective Tissue DiseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 May 2026